Abstract
Biologics have become a rising treatment for many diseases, such as cancer, hormone repositioning, vaccines, and many others. The increased use of biologics raised attention to drug spending in this treatment niche. Thus, as patent exclusivities for a biologic expire, biosimilars are produced and gain room as a treatment alternative. However, subtle differences in the structure do not mak…